SAN FRANCISCO and VANCOUVER, British Columbia — August 13, 2025 — Leads & Copy — Jade Biosciences, Inc. (Nasdaq: JBIO) has announced financial results for the quarter ending June 30, 2025, and provided a corporate update. Preclinical data for JADE101 was presented at the 62nd European Renal Association Congress, highlighting its potential as an anti-APRIL monoclonal antibody for IgA nephropathy. A Phase 1 healthy-volunteer study of JADE101 is expected to begin in the third quarter of 2025, with interim data anticipated in the first half of 2026.
As of June 30, 2025, Jade Biosciences had $220.9 million in cash and cash equivalents, which supports operations through 2027. The company’s pipeline includes JADE101 and JADE201, with JADE201 expected to enter the clinic in the first half of 2026. Brad Dahms has been appointed as Chief Financial Officer.
Second quarter 2025 financial results include R&D expenses of $22.5 million and G&A expenses of $5.2 million. Net loss for the quarter totaled $32.1 million. As of June 30, 2025, Jade had 52.6 million shares outstanding.
Jade Biosciences is focused on developing therapies for autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy.
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
Source: Jade Biosciences, Inc.
